Alkermes (ALKS) Commences ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Alkermes (ALKS) Commences ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

Alkermes (ALKS) Tops Q3 EPS by 8c

October 27, 2021 7:05 AM EDT

Alkermes (NASDAQ: ALKS) reported Q3 EPS of $0.14, $0.08 better than the analyst estimate of $0.06. Revenue for the quarter came in at $294.1 million versus the consensus estimate of $301.59 million.

For earnings history and earnings-related data on Alkermes (ALKS) click here.

... More

Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

October 25, 2021 7:00 AM EDT

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant... More